WO2009147121A1 - Indoles à substitution carboxyle destinés à être utilisés en tant que modulateurs du ppar-alpha - Google Patents

Indoles à substitution carboxyle destinés à être utilisés en tant que modulateurs du ppar-alpha Download PDF

Info

Publication number
WO2009147121A1
WO2009147121A1 PCT/EP2009/056708 EP2009056708W WO2009147121A1 WO 2009147121 A1 WO2009147121 A1 WO 2009147121A1 EP 2009056708 W EP2009056708 W EP 2009056708W WO 2009147121 A1 WO2009147121 A1 WO 2009147121A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
indole
amino
carboxylic acid
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/056708
Other languages
English (en)
Inventor
Nicolas Eric Faucher
Paul Martres
Stephane Meunier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of WO2009147121A1 publication Critical patent/WO2009147121A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to indole derivatives, compositions and medicaments containing said indole derivatives and processes for their preparation.
  • the invention also relates to the use of said indole derivatives, compositions and medicaments, for example as activators of the alpha subtype of the human peroxisome proliferator activated receptor (hPPAR) and/or for the treatment of disorders mediated by hPPAR alpha.
  • hPPAR human peroxisome proliferator activated receptor
  • HMG CoA reductase inhibitors are useful for treating conditions characterized by high LDL-c levels. It has been shown that lowering LDL-c is not sufficient for reducing the risk of cardiovascular disease in some patients, particularly those with normal LDL-c levels. This population pool is identified by the independent risk factor of low HDL-c.
  • the increased risk of cardiovascular disease associated with low HDL-c levels has not yet been successfully addressed by drug therapy (i.e., currently there are no drugs on the market that are useful for raising HDL-c >40%). (Bisgaier, C. L.; Pape, M. E. Curr. Pharm. Des. 1998, 4, 53-70).
  • Syndrome X (including metabolic syndrome) is loosely defined as a collection of abnormalities including hyperinsuinlemia, obesity, elevated levels of trigycerides, uric acid, fibrinogen, small dense LDL-c particles, and plasminogen activator inhibitor 1 (PAI-1 ), and decreased levels of HDL-c.
  • abnormalities including hyperinsuinlemia, obesity, elevated levels of trigycerides, uric acid, fibrinogen, small dense LDL-c particles, and plasminogen activator inhibitor 1 (PAI-1 ), and decreased levels of HDL-c.
  • NIDDM is described as insulin resistance which in turn causes anomalous glucose output and a decrease in glucose uptake by skeletal muscle. These factors eventually lead to impaired glucose tolerance (IGT) and hyperinsulinemia.
  • ITT impaired glucose tolerance
  • Peroxisome Proliferator Activated Receptors are orphan receptors belonging to the steroid/retinoid receptor superfamily of ligand-activated transcription factors. See, for example, Willson, T. M. and Wahli, W., Curr. Opin. Chem. Biol., (1997), Vol. 1 , pp 235- Three mammalian Peroxisome Proliferator-Activated Receptors have been isolated and termed PPAR-alpha, PPAR-gamma, and PPAR-delta (also known as NUC1 or PPAR- beta). These PPARs regulate expression of target genes by binding to DNA sequence elements, termed PPAR response elements (PPRE).
  • PPRE PPAR response elements
  • Certain compounds that activate or otherwise interact with one or more of the PPARs have been implicated in the regulation of triglyceride and cholesterol levels in animal models. See, for example, WO 01/40207, WO 01/00603, WO 97/31907, WO 02/46174 (Glaxo Group Ltd et al).
  • R 1 and R 2 is H, the other is COOH;
  • R 3 is H or -CH 2 N(CHa) 2 ;
  • Z is C 3-7 cycloalkyl, phenyl (optionally substituted by -C 1-3 alkoxy, -OH, -C 1-3 alkyl), a 5 or 6 membered monocyclic heteroaryl (optionally substituted by -C 1-3 alkyl), benzothiophenyl or benzofuranyl;
  • X is a linker group of 6 or 7 above in shortest length between N and Y.
  • Y is (a) phenyl (substituted by one, two or three substituents, each independently selected from -OH, -Cr 3 alkyl, -Cr 3 alkoxy, -Ci -3 haloalkyl, halogen, -C 5-6 cycloalkyl, a 5 or 6 membered monocyclic heteroaryl, -NR a R b (wherein R a and R b are independently selected from H or -Ci- 3 alkyl); (b) phenyl fused to a 5 or 6 membered heterocyclic ring containing one or two oxygen atoms (said phenyl and heterocyclic ring each being optionally substituted by -Ci -3 alkyl);
  • R 7 is H or -Cr 3 alkyl
  • R 8 is H or -Cr 3 alkyl.
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.
  • a method of treating hPPAR mediated disorders in a subject comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in the treatment of hPPAR mediated disorders.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of hPPAR mediated disorders there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of hPPAR mediated disorders.
  • alkyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms.
  • C 1-6 alkyl means a straight or branched alkyl chain containing at least 1 , and at most 6 carbon atoms.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, t-butyl, n-pentyl.
  • cycloalkyl refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms.
  • C 3 - 7 cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms.
  • Examples of "cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I), and the radicals, thereof, fluoro (-F), chloro (-Cl), bromo (-Br) and iodo (-I).
  • C 1 -C 6 haloalkyl refers to an alkyl group as defined above containing at least 1 , and at most 6, carbon atoms substituted with at least one halo group, halo being as defined herein.
  • Examples of branched or straight chained "C 1 -C 6 haloalkyl” groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted independently with one or more halos, e.g., fluoro, chloro, bromo and iodo.
  • alkoxy refers to the group R 3 O-, where R 3 is alkyl as defined above and the term "C 1 -C 6 alkoxy” refers to an alkoxy group as defined herein wherein the alkyl moiety contains at least 1 , and at most 6, carbon atoms.
  • Exemplary C 1 -C 6 alkoxy groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n- propoxy, isopropoxy, n-butoxy, and t-butoxy.
  • heterocyclic or the term “heterocyclyl” refers to a non-aromatic three to seven-membered (unless otherwise specified) heterocyclic ring being saturated or having one or more degrees of unsaturation containing one or more oxygen atoms.
  • heteroaryl refers to a monocyclic aromatic ring having the specified number of carbon atoms, and which contains one or more nitrogen, sulphur, and/or oxygen heteroatoms, where N-oxides and sulphur oxides and dioxides are permissible heteroatom substitutions.
  • heteroaryl groups used herein include furanyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridyl, pyridazyl, pyrazinyl, pyrimidyl.
  • hPPAR activator is used to mean a compound which binds to and activates hPPAR, for example in the binding and transfection assays described below.
  • hPPAR mediated disorders is used to mean any disorder mediated or modulated by hPPAR, including dyslipidemia (including associated diabetic dyslipidemia and mixed dyslipidemia), obesity, syndrome X (as defined in this application this embraces metabolic syndrome), heart failure, hypercholesteremia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type Il diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, Alzheimers disease or other cognitive disorders, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lining and gut, regulation of appetite and food intake in subjects suffering from disorders such as obesity, bulimia, and anorexia nervosa, Alzheimers disease, multiple sclerosis and other cognitive disorders.
  • dyslipidemia including associated diabetic dyslipidemia and mixed dyslipidemia
  • obesity syndrome X (as defined in this application this embraces metabolic syndrome)
  • heart failure hypercholesteremia
  • cardiovascular disease including atherosclerosis,
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I), or a salt thereof) and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include, but are not limited to, water, acetone, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent is water.
  • the compounds of formula (I) may have the ability to crystallize in more than one form, a characteristic, which is known as polymorphism, and it is understood that such polymorphic forms (“polymorphs”) are within the scope of formula (I).
  • Polymorphism generally can occur as a response to changes in temperature or pressure or both and can also result from variations in the crystallization process. Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility and melting point.
  • the compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers. Accordingly, the compounds of this invention include mixtures of enantiomers as well as purified enantiomers or enantiomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula (I) above as well as any wholly or partially equilibrated mixtures thereof. The present invention also covers the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centres are inverted.
  • the compounds of the invention may form tautomers. It is understood that all tautomers and mixtures of tautomers of the compounds of the present invention are included within the scope of the compounds of the present invention.
  • R 2 is H and R 1 is COOH
  • R 3 is H.
  • Z represents phenyl (optionally substituted by OH or -OCH 3 ), cyclohexyl, a monocyclic 5 or 6 membered heteroaryl (optionally substituted by CH 3 ), a benzothiophenyl or benzofuranyl.
  • Z represents phenyl, furanyl, benzofuranyl, benzothiophenyl, pyridinyl, thiophenyl (substituted by -CH 3 ), phenyl (substituted by OH), phenyl (substituted by - CH 3 ), cyclohexyl.
  • Z represents phenyl
  • X represents a linker group selected from -(CH 2 ) 4 NR C C(O) -, -(CH 2 ) 4 C(O)NH -, -(CH 2 ) 2 O CH 2 C(O)NH -,
  • X represents -(CH 2 ⁇ NHCO-, or -(CH 2 ⁇ OCH 2 CONH-,
  • Y is phenyl (optionally substituted by one or more substituents independently selected from d- 3 alkyl, OH, d- 3 haloalkyl, -halogen, d- 3 alkoxy, C 5-6 cycloalkyl), a 5 or 6 membered heteroaryl, NR x R y (wherein R x and R y are independently H or Cr 3 alkyl), phenyl fused to a 5 membered heterocylic ring containing one O atom, phenyl fused to a 6 membered heterocyclic ring containing two O atoms.
  • Y is
  • X is independently selected from C r3 alkyl, C r3 alkoxy, OH, cycloalkyl, NR x R y (R x and R y are independently C r3 alkyl), chloro, CF 3 , pyridyl),
  • n is 1 , 2 or 3 and each X is independently selected from Cr 3 alkyl, Cr 3 alkoxy, COH, cycloalkyl, NR x R y (R x and R y are independently C r3 alkyl), chloro, CF 3 , pyridyl).
  • Z is phenyl
  • X is -(CH 2 ⁇ OCH 2 CONH-
  • Y is phenyl, (substituted by -C 1- 3 alkyl).
  • Example 1 1- ⁇ 2-[(2- ⁇ [4-(1-methylethyl)phenyl]amino ⁇ -2-oxoethyl)oxy]ethyl ⁇ -3-phenyl-1 /-/-indole-6- carboxylic acid;
  • Example 6 1- ⁇ 2-[(2- ⁇ [3-(1-methylethyl)phenyl]amino ⁇ -2-oxoethyl)oxy]ethyl ⁇ -3-phenyl-1 H-indole-6- carboxylic acid;
  • Example 1 1 1- ⁇ 2-[(2- ⁇ [4-(1 ,1-dimethylethyl)phenyl]amino ⁇ -2-oxoethyl)oxy]ethyl ⁇ -3-phenyl-1 H-indole-6- carboxylic acid;
  • Example 12 1- ⁇ 2-[(2- ⁇ [4-(1 ,1-dimethylethyl)phenyl]amino ⁇ -2-oxoethyl)oxy]ethyl ⁇ -3-phenyl-1 H-indole-6- carboxylic acid;
  • Example 13 1-[2-( ⁇ 2-[(4-ethylphenyl)amino]-2-oxoethyl ⁇ oxy)ethyl]-3-phenyl-1 H-indole-6-carboxylic acid;
  • Example 21 1-(4- ⁇ [(4-methylphenyl)carbonyl]amino ⁇ butyl)-3-phenyl-1 H-indole-6-carboxylic acid;
  • Example 27 1 - ⁇ 4-[( ⁇ 4-[methyl(propyl)amino]phenyl ⁇ carbonyl)amino]butyl ⁇ -3-phenyl-1 H-indole-6- carboxylic acid;
  • Example 34 1 -[4-(2-methyl-4-oxo-3(4H)-quinazolinyl)butyl]-3-phenyl-1 H-indole-6-carboxylic acid;
  • Example 42 1 - ⁇ 4-[(2,3-dihydro-1 ,4-benzodioxin-6-ylcarbonyl)amino]butyl ⁇ -3-phenyl-1 H-indole-6- carboxylic acid;
  • Example 46 1-(2- ⁇ 4-[4-(1-Methylethyl)phenyl]-1-piperazinyl ⁇ -2-oxoethyl)-3-phenyl-1 H-indole-6- carboxylic acid;
  • Example 51 3-(1-benzothien-2-yl)-1-[4-( ⁇ [4-(1-methylethyl)phenyl]carbonyl ⁇ amino)butyl]-1 H-indole-6- carboxylic acid;
  • Example 52 3-(1-benzothien-2-yl)-1-[4-( ⁇ [4-(1-methylethyl)phenyl]carbonyl ⁇ amino)butyl]-1 H-indole-6- carboxylic acid;
  • Example 55 1-[(4- ⁇ [(4-cyclohexylphenyl)carbonyl]amino ⁇ phenyl)methyl]-3-phenyl-1 H-indole-6- carboxylic acid;
  • the compounds of the invention are modulators of human PPARs, particularly PPAR alpha and PPAR gamma. In one aspect they are agonists or partial agonists.
  • the hPPAR agonists of formula (I) may be agonists of only one hPPAR ("selective agonists"), agonists for two hPPAR subtypes ("dual agonists"), or agonists for all three hPPAR subtypes ("pan agonists").
  • agonist or “activating compound”, or “activator”, or the like, is meant those compounds which have a pKi of at least 6.0 preferably at least 7.0 to the relevant PPAR, for example hPPAR alpha in the binding assay described below, and which achieve at least 50% activation of the relevant PPAR relative to the appropriate indicated positive control in the transfection assay described below at concentrations of 10 "5 M or less.
  • EC 50 is defined in the transfection assay described below and is the concentration at which a compound achieves 50% of its maximum activity.
  • Partial agonists can be defined as compounds that transactivate the relevant PPAR, for example PPAR alpha in CV1 cells with less than 50% fold activation compared to the reference PPAR alpha full agonist in the transfection assays of the type described below.
  • the compounds of formula (1 ) are hPPAR alpha agonists.
  • the compounds of Formula (I) may be in the form of a salt.
  • the salts of the present invention are pharmaceutically acceptable salts.
  • Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. For a review on suitable salts see Berge et al, J. Pharm. Sci. 1977, 66, 1-19.
  • Suitable pharmaceutically acceptable salts can include acid addition salts.
  • a pharmaceutically acceptable acid addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic acid (such as hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, p-toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-naphthalenesulfonic), optionally in a suitable solvent such as an organic solvent, to give the salt which is usually isolated for example by crystallisation and filtration.
  • a suitable inorganic or organic acid such as hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, p-toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-naphthalenesulfonic
  • a suitable solvent such as an organic solvent
  • a pharmaceutically acceptable acid addition salt of a compound of formula (I) can comprise or be for example a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate (e.g. 2- naphthalenesulfonate) salt.
  • non-pharmaceutically acceptable salts e.g. trifluoroacetates
  • the invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the compounds of formula (I).
  • the compounds of the invention are believed to be activators of hPPAR alpha, and thus be potentially useful in the treatment of hPPAR mediated disorders.
  • the invention thus provides a compound of formula (I) or a pharmaceutically acceptable salts thereof for use in therapy, and particularly in the treatment of hPPAR mediated disorders.
  • a method of treating hPPAR mediated disorders comprising administering to a subject a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the subject is a mammal, particularly a human.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in the treatment of hPPAR mediated disorders.
  • hPPAR mediated diseases or conditions include dyslipidemia (including associated diabetic dyslipidemia and mixed dyslipidemia), syndrome X (as defined in this application this embraces metabolic syndrome), heart failure, hyperchloresterolemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type Il diabetes mellitus, type 1 diabetes, insulin resistance, hyperlipidemia, obesity, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lung and gut and regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia, and anorexia nervosa, cancer, Alzheimers disease, multiple sclerosis or other cognitive disorders.
  • the compounds of this invention are useful in the treatment and prevention of diabetes and cardiovascular diseases and conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and dyslipidaemia.
  • the invention further provides pharmaceutical compositions comprising a compound of the formula (I) or a pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
  • a process for the preparation of a pharmaceutical composition including admixing a compound of the formula (I), or pharmaceutically acceptable salts thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the pharmaceutical composition can be for use in the treatment and/or prophylaxis of any of the conditions described herein. Since the compounds of the invention are intended for use in pharmaceutical compositions it will be readily understood that they are each preferably provided in substantially pure form, for example, at least 60% pure, more suitably at least 75% pure and preferably at least 85% pure, especially at least 98% pure (% in a weight for weight basis).
  • compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
  • Preferred unit dosage compositions are those containing a daily dose or sub-dose, or an appropriate fraction thereof, of an active ingredient. Such unit doses may therefore be administered once or more than once a day.
  • Such pharmaceutical compositions may be prepared by any of the methods well known in the pharmacy art.
  • compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, inhaled, intranasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route.
  • Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
  • compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • Powders are prepared by reducing the compound to a suitable fine size and mixing with a similarly prepared pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
  • Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths.
  • Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation.
  • a disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
  • suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
  • a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
  • the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
  • the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
  • the lubricated mixture is then compressed into tablets.
  • the compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
  • a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
  • Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
  • Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
  • Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
  • dosage unit compositions for oral administration can be microencapsulated.
  • the composition can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
  • the compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • compositions are preferably applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water- miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
  • compositions adapted for rectal administration may be presented as suppositories or as enemas.
  • Dosage forms for nasal or inhaled administration may conveniently be formulated as aerosols, solutions, suspensions drops, gels or dry powders.
  • compositions suitable and/or adapted for inhaled administration it is preferred that the compound or salt of formula (I) is in a particle-size-reduced form, and more preferably the size-reduced form is obtained or obtainable by micronisation.
  • the preferable particle size of the size-reduced (e.g. micronised) compound or salt or solvate is defined by a D50 value of about 0.5 to about 10 microns (for example as measured using laser diffraction).
  • compositions adapted for administration by inhalation include the particle dusts or mists.
  • compositions wherein the carrier is a liquid for administration as a nasal spray or drops include aqueous or oil solutions/suspensions of the active ingredient which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators.
  • Aerosol formulations can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or nonaqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device or inhaler. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.
  • a metering valve metered dose inhaler
  • the dosage form comprises an aerosol dispenser
  • it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide or an organic propellant such as a hydrofluorocarbon (HFC).
  • suitable HFC propellants include 1 ,1 ,1 ,2,3,3,3-heptafluoropropane and 1 ,1 ,1 ,2-tetrafluoroethane.
  • the aerosol dosage forms can also take the form of a pump-atomiser.
  • the pressurised aerosol may contain a solution or a suspension of the active compound. This may require the incorporation of additional excipients e.g. co-solvents and/or surfactants to improve the dispersion characteristics and homogeneity of suspension formulations.
  • Solution formulations may also require the addition of co-solvents such as ethanol.
  • Other excipient modifiers may also be incorporated to improve, for example, the stability and/or taste and/or fine particle mass characteristics (amount and/or profile) of the formulation.
  • the pharmaceutical composition may be a dry powder inhalable composition.
  • Such a composition can comprise a powder base such as lactose, glucose, trehalose, mannitol or starch, the compound of formula (I) or salt or solvate thereof (preferably in particle-size- reduced form, e.g. in micronised form), and optionally a performance modifier such as L- leucine or another amino acid, cellobiose octaacetate and/or metals salts of stearic acid such as magnesium or calcium stearate.
  • a performance modifier such as L- leucine or another amino acid, cellobiose octaacetate and/or metals salts of stearic acid such as magnesium or calcium stea
  • Aerosol formulations are preferably arranged so that each metered dose or "puff" of aerosol contains a particular amount of a compound of the invention. Administration may be once daily or several times daily, for example 2, 3 4 or 8 times, giving for example 1 , 2 or 3 doses each time.
  • the overall daily dose and the metered dose delivered by capsules and cartridges in an inhaler or insufflator will generally be double those with aerosol formulations.
  • compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the compositions may be presented in unit- dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • compositions may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • a therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the subject , the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian.
  • the subject to be treated is a mammal, particularly a human.
  • the pharmaceutically acceptable compounds or salts of the invention may be administered in a daily dose (for an adult patient) of, for example, an oral or parenteral dose of 0.01 mg to 100 mg/kg per day body weight. This amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub- doses per day such that the total daily dose is the same.
  • An effective amount of a salt or solvate, thereof, may be determined as a proportion of the effective amount of the compound of formula (I) per se.
  • the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same.
  • An effective amount of a salt or solvate, or physiologically functional derivative thereof, may be determined as a proportion of the effective amount of active ingredient.
  • the compounds of the present invention may be employed alone or in combination with other therapeutic agents.
  • the invention provides a combination comprising at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one other pharmaceutically active agent.
  • combination therapies according to the present invention comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one other pharmaceutically active agent.
  • the compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together in a single pharmaceutical composition or separately and, when administered separately this may occur simultaneously or sequentially in any order. When administered separately, they may be at different times of the day.
  • the amounts of the compound(s) of formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • the compound and pharmaceutical compositions according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from statins (HMG Co A reductase inhibitors) and/or other lipid lowering drugs for example MTP inhibitors and LDLR upregulators.
  • the compounds of the invention may also be used in combination with antidiabetic agents, e.g. metformin, sulfonylureas and/or PPAR activators (for example thiazolidinediones such as e.g. pioglitazone and rosiglitazone).
  • the compounds may also be used in combination with antihypertensive agents such as angiotensin antagonists calcium channel antagonists and ACE inhibitors.
  • the invention thus provides in a further aspect the use of a combination comprising a compound of formula (I) with a further therapeutic agent in the treatment of a hPPAR mediated disorders.
  • the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
  • the compounds When a compound of formula (I) is used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.
  • compositions comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions.
  • the two compounds When combined in the same composition it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the composition and may be formulated for administration. When formulated separately they may be provided in any convenient composition, conveniently in such a manner as are known for such compounds in the art.
  • the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
  • R 1 is depicted as H and R 2 as COOH.
  • the schemes are equally applicable to those compounds of formula (I) wherein R 1 is COOH and R 2 is H.
  • P, P and P" are independently C 1-6 alkyl or another suitable protecting group.
  • X is -(CH 2 ) 4 NHC 17 - may be prepared by the following scheme
  • Z can be introduced in the molecule either before or after the -XY group.
  • reaction mixture was stirred until room temperature was reached, then poured into 2L of an ice/water mixture.
  • the precipitate was filtered then solubilised with 2L of ethyl acetate and washed twice with brine.
  • the solution was dried with Na 2 SO 4 then concentrated "in vacuum.”
  • Example 1 was re-crystallized in acetonitrile : yield of the re-crystallisation (80%) NMR 1 H NMR (300 MHz), CDCI3 ⁇ : 8.33 (s, 1 H), 8.03 (m, 2H), 7.65 (d, 3H), 7.58 (s, 1 H), 7.48 (t, 2H), 7.35 (m, 1 H), 7.28 (s, 1 H), 7.02 (s, 2H), 4.58 (m, 2H), 4.08 (s, 2H), 4.01 (m, 2H), 2.80 (m, 1 H), 1.17 (d, 6H).
  • Example 46 was prepared in an analogous manner to Example 1 from Methyl 1-(2- ⁇ 4-[4-]
  • RMN CDCI3 ⁇ : 8.11 (s, 1 H), 7.81 (d, 1 H), 7.74 (s, 1 H), 7.71 (d, 1 H), 7.46 (s, 1 H), 7.40 (m, 1 H), 6.63 (s, 1 H), 3.88 (s, 3H).
  • Binding Assay Compounds were tested for their ability to bind to hPPAR gamma hPPARalpha or PPARdelta using a Scintillation Proximity Assay (SPA).
  • SPA Scintillation Proximity Assay
  • the PPAR ligand binding domain (LBD) was expressed in E. coli as polyHis tagged fusion proteins and purified. The LBD was then labelled with biotin and immobilised on streptavidin-modified scintillation proximity beads.
  • the beads were then incubated with a constant amount of the appropriate radioligand (5- ⁇ 4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl ⁇ -thiazolidine- 2,4-dione ⁇ J.Med.Chem. 1994, 37(23), 3977), for PPARgamma), and labelled GW 2433 (see Brown, P. J et al . Chem. Biol., 4, 909-918 (1997), for the structure and synthesis of this ligand) for PPAR alpha and PPAR delta) and variable concentrations of test compound, and after equilibration the radioactivity bound to the beads was measured by a scintillation counter.
  • the appropriate radioligand 5- ⁇ 4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl ⁇ -thiazolidine- 2,4-dione ⁇ J.Med.Chem. 1994, 37(23), 3977
  • An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma), J. Biol. Chem., 270, 12953-6 (1995).
  • the ligand binding domains for murine and human PPAR alpha, PPAR gamma, and PPAR delta were each fused to the yeast transcription factor GAL4 DNA binding domain.
  • CV-1 cells were transiently transfected with expression vectors for the respective PPAR chimera along with a reporter construct containing five copies of the GAL4 DNA binding site driving expression of secreted placental alkaline phosphatase (SPAP) and beta-galactosidase.
  • SPAP secreted placental alkaline phosphatase
  • the positive control in the hPPAR alpha assays was 2-4-[2-(3-[4-fluorophenyl]-1- heptylureido)ethyl]-phenoxy-(2-methyl propionic acid (WO 97/36579).
  • the positive control for PPAR delta assays was 2- ⁇ 2-methyl-4-[( ⁇ 4-methyl-2- ⁇ trifluoromethyl)phenyl]-1 ,3- thiazol-5-yl ⁇ methyl)sulfanyl]phenoxy ⁇ acetic acid (WO 01/00603).
  • the positive control was (5- ⁇ 4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl ⁇ -thiazolidine-2,4-dione (J. Med. Chem. 1994, 37(23), 3977), for PPAR gamma.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L’invention concerne de nouveaux composés représentés par la formule (I), ou des sels ou solvates pharmaceutiquement acceptables associés, l’un de R1 et R2 étant H et l’autre étant COOH. Les composés sont utiles en tant que modulateurs du PPAR.
PCT/EP2009/056708 2008-06-02 2009-06-02 Indoles à substitution carboxyle destinés à être utilisés en tant que modulateurs du ppar-alpha Ceased WO2009147121A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5795708P 2008-06-02 2008-06-02
US61/057,957 2008-06-02

Publications (1)

Publication Number Publication Date
WO2009147121A1 true WO2009147121A1 (fr) 2009-12-10

Family

ID=41397752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/056708 Ceased WO2009147121A1 (fr) 2008-06-02 2009-06-02 Indoles à substitution carboxyle destinés à être utilisés en tant que modulateurs du ppar-alpha

Country Status (1)

Country Link
WO (1) WO2009147121A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013152065A2 (fr) 2012-04-05 2013-10-10 Boehringer Ingelheim International Gmbh Composés inhibiteurs de cytomégalovirus
EP3137074A4 (fr) * 2014-04-29 2017-11-15 Emory University Antagonistes du récepteur ep2 des prostaglandines, dérivés, compositions et utilisations associés
US12240829B2 (en) 2019-03-20 2025-03-04 Emory University Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030895A1 (fr) * 2000-10-10 2002-04-18 Smithkline Beecham Corporation Indoles substituees, compositions pharmaceutiques contenant ces indoles et leur utilisation comme agent de fixation de ppar-$g(g)
WO2009047240A1 (fr) * 2007-10-09 2009-04-16 Smithkline Beecham Corporation Dérivés d'indole utiles comme activateurs de ppar

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030895A1 (fr) * 2000-10-10 2002-04-18 Smithkline Beecham Corporation Indoles substituees, compositions pharmaceutiques contenant ces indoles et leur utilisation comme agent de fixation de ppar-$g(g)
WO2009047240A1 (fr) * 2007-10-09 2009-04-16 Smithkline Beecham Corporation Dérivés d'indole utiles comme activateurs de ppar

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013152065A2 (fr) 2012-04-05 2013-10-10 Boehringer Ingelheim International Gmbh Composés inhibiteurs de cytomégalovirus
EP3137074A4 (fr) * 2014-04-29 2017-11-15 Emory University Antagonistes du récepteur ep2 des prostaglandines, dérivés, compositions et utilisations associés
US10568889B2 (en) 2014-04-29 2020-02-25 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US11077120B2 (en) 2014-04-29 2021-08-03 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US12240829B2 (en) 2019-03-20 2025-03-04 Emory University Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto

Similar Documents

Publication Publication Date Title
WO2009047240A1 (fr) Dérivés d'indole utiles comme activateurs de ppar
WO2009147121A1 (fr) Indoles à substitution carboxyle destinés à être utilisés en tant que modulateurs du ppar-alpha
JP5305914B2 (ja) オキサゾール化合物及び医薬組成物
CA2536870C (fr) Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
CN102791690B (zh) 作为抗癌药的二取代吡啶衍生物
EP2172447A1 (fr) Composé amide
EP1562915A1 (fr) Agonistes de recepteur farnesoide x
BRPI0413991B1 (pt) composto ativador de ppar e composição farmacêutica contendo o mesmo
JP2007502264A (ja) Ｈｍ７４ａ受容体アゴニストとしての２−置換安息香酸誘導体
EP1480957A1 (fr) Activateurs de hppars
JP2007532563A5 (fr)
SK168097A3 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
AU4689500A (en) Di-aryl acid derivatives as ppar receptor ligands
EP1349843A1 (fr) Derives de thiazole et d'oxazole en tant qu'activateurs de recepteurs actives par le proliferateur du peroxysome humain
CA2693552A1 (fr) Compose de pyridone
JP2008515998A (ja) 化合物
KR20090005383A (ko) Ｃ-ｆｍｓ 키나제의 저해제
EP1729756A2 (fr) Nouvelles compositions pharmaceutiques
JP2006524687A (ja) バニロイド受容体で阻害活性を示す新規複素環アミド
US20040147571A1 (en) Substituted oxazoles and thiazoles as hppar alpha agonists
JP4986927B2 (ja) 医薬
CN101563322A (zh) 用作ppar调节剂的1h-吲哚-2-甲酸衍生物
AU2002220902B2 (en) 1, 2, 4-oxadiazole derivatives as hppar alpha agonists
CN100425594C (zh) Ppar活性化化合物及含该化合物的医药组合物
CN105164112A (zh) 酰胺类化合物及其制备方法、药物组合物和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09757502

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09757502

Country of ref document: EP

Kind code of ref document: A1